BW

GALT polyclonal Antibody | BS8105

(No reviews yet) Write a Review
SKU:
BW-BS8105
Availability:
Usually ships in 5 working days
NULL444.00 - NULL678.00

Description

GALT polyclonal Antibody | BS8105 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: WB IHC

Application Range: WB: 1:500~1:2000 IHC: 1:50~1:200

Background: GALT (galactose-1-phosphate uridylyltransferase) is a 379 amino acid member of the galactose-1-phosphate uridylyltransferase type 1 family of proteins. GALT exists as a homodimer and is believed to play a role in galactose metabolism. More specifically, GALT is responsible for catalyzing the reaction of UDP-glucose with α-D-galactose 1-phosphate to produce α-D-glucose 1-phosphate and UDP-galactose. This is the second step of the Leloir pathway of galactose metabolism. The products of this reaction will either enter the glycolytic pathway to yield energy (α-D-glucose 1-phosphate) or be used as a galactosyl donor in the synthesis of glycoproteins and glycolipids (UDP-galactose) . Mutations in the gene encoding GALT can lead to galactosemia, a disorder (occurring from the inability to metabolize galactose) that is characterized by cataracts, mental retardation and jaundice. In newborns, galactosemia can be fatal if lactose is not removed from the diet.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: GALT polyclonal Antibody detects endogenous levels of GALT protein.

Molecular Weight: Refer to Figures

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: Galactose-1-phosphate uridylyltransferase; Gal-1-P uridylyltransferase; UDP-glucose--hexose-1-phosphate uridylyltransferase; GALT

Immunogen: Recombinant full length Human GALT.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway:

View AllClose